Top banner. Pluvicto▼ (lutetium Lu 177 vipivotide tetraxetan) branded banner. Image of 3 older men. Text 'Pluvicto is currently available for eligible privately treated patients in Great Britain'.

This is a promotional website intended for UK healthcare professionals. If you are a member of the public, please click here.

Welcome to the Radioligand Therapy Hub.

Please confirm whether you are a UK healthcare professional or a member of the public. This website is not suitable for healthcare professionals outside of the United Kingdom.

I am a UK Healthcare Professional

No, I am a member of the public

Search Results

RLT Home
Neuroendocrine tumours
Prostate cancer

Popular Search

prrt
masterclass
part
2022
2023

Ask Speakers

Medical Information Request

Welcome to the Radioligand Therapy Hub.

Please confirm whether you are a UK healthcare professional or a member of public.

Yes, I am a UK healthcare professional

No, I am a member of the public

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]

Cookie Settings

Site directory

This site is intended for a UK healthcare professional audience and NHS relevant decision makers only.

Novartis Pharmaceuticals UK Limited is a limited liability company registered in England and Wales under number 119006.
Registered office: The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ

UK | April 2024 | AAA-Lu177-UK-2429